+

Cookies on the Business Insider India website

Business Insider India has updated its Privacy and Cookie policy. We use cookies to ensure that we give you the better experience on our website. If you continue without changing your settings, we\'ll assume that you are happy to receive all cookies on the Business Insider India website. However, you can change your cookie setting at any time by clicking on our Cookie Policy at any time. You can also see our Privacy Policy.

Close
HomeQuizzoneWhatsappShare Flash Reads
 

Valeant's stock is getting stomped again

Oct 22, 2015, 19:38 IST

J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., gestures during their annual general meeting in Laval, Quebec May 20, 2014.REUTERS/Christinne Muschi

Shares of Canadian pharmaceutical company Valeant cratered again on Thursday morning.

Advertisement

The share price was last down 15% at about $101.57. So far this week, the stock has fallen more than 42%.

The stock fell on Wednesday after short-selling-firm Citron Research published a report accusing Valeant of being an Enron-like fraud.

Much of Citron's report focuses on Valeant's mysterious relationship with Philidor, a specialty pharmacy that distributes and books prescription drugs for big drug companies.

Valeant is the only customer of Philidor and it also has an option to buy the company. Citron accuses Valeant of using Philidor, and an unknown number of specialty pharmacies like it to generate fake invoices so that it can book revenue for sales that never happened.

Advertisement

The report also draws comparisons to Enron that are "too close to ignore."

"We categorically deny the allegations made in the Citron Report," Valeant said in a statement. "Citron's false and misleading statements about Valeant appear to be an attempt to manipulate the market in an effort to drive down Valeant's stock price."

A number of Wall Street analysts have weighed in on the matter. The reaction has been mixed. Some see the share price collapse as a buying opportunity, while others think it's best to wait it out. Others just don't know.

Valeant has been a popular stock amongst hedge funds. It ranked No. 10 on Goldman Sachs' stocks that "matter most" to hedge funds list for the second quarter. According to Goldman, 32 funds had the stock as one of their top-10 stock holdings.

Activist investor Bill Ackman, the founder of $19 billion Pershing Square Capital Management, is the largest hedge fund shareholder and the third largest shareholder overall. He's lost more than $1 billion on paper on the position so far. During Wednesday's decline, Ackman said that he bought 2 million more shares, bringing his total stake to 21.47 million shares.

Advertisement

Here's a five day chart:

Google Finance

NOW WATCH: This is what Carl Icahn would do first if he ruled America

Please enable Javascript to watch this video
You are subscribed to notifications!
Looks like you've blocked notifications!
Next Article